Costs, quality of life, treatment satisfaction and compliance in patients with β-thalassemia major undergoing iron chelation therapy: the ITHACA study

References

• Wolman IJ. Transfusion therapy in Cooley's anemia: growth and health as related to long-range hemoglobin levels, a progress report. Ann NY Acad Sci 1964; 119:736–52
   PubMed Web of Science ®Google Scholar
• Piomelli S, Danoff SJ, Becker MH, . Prevention of bone malformations and cardiomegaly in Cooley's anemia by early hypertransfusion regimen. Ann NY Acad Sci 1969; 165:427–36
   PubMed Web of Science ®Google Scholar
• Barry M, Flynn DN, Letsky EA, . Long-term chelation therapy in thalassemia major: effect on liver iron concentration, liver histology and clinical progress. Br Med J 1974; 2:16–20
   PubMed Web of Science ®Google Scholar
• Hussain MA, Green N, Flynn DM, . Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload. Lancet 1976; 2:1278–80
   PubMed Web of Science ®Google Scholar
• Modell CB, Beck J. Long-term desferrioxamine therapy in thalassemia. Ann NY Acad Sci 1974; 232:201–10
   PubMed Web of Science ®Google Scholar
• Zurlo MG, De Stefano P, Borgna-Pignatti C, . Survival and causes of death in thalassaemia major. Lancet 1989; 8653:27–30
   Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, . Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89:1187–93
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, . Survival and disease complications in thalassemia major. Ann NY Acad Sci 1998; 850:227–31
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Nathan DG, MacMillan JH, . Survival in medically treated patients with homozygous β-thalassemia. New Engl J Med 1994; 331:574–8
   PubMed Web of Science ®Google Scholar
• Cohen AR, Galanello R, Piga V, . Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102:1583–7
   PubMed Web of Science ®Google Scholar
• Piga A, Gaglioti C, Fogliacco E, . Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88:489–96
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Berdoukas V, Karagiorga M, . Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107:3738–44
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, . A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115:1876–84
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Piga A, . A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107:3455–62
   PubMed Web of Science ®Google Scholar
• Woods K, Karrison T, Koshy M, . Hospital utilization patterns and costs for adult sickle cell patients in Illinois. Public Health Rep 1997; 112:44–51
   PubMed Web of Science ®Google Scholar
• Ginsberg G, Tulchinsky T, Filon D, . Cost benefit analysis of a national thalassaemia prevention programme in Israel. J Med Screen 1998; 5:120–6
   PubMed Web of Science ®Google Scholar
• Nietert PJ, Abboud MR, Zoller JS, . Costs, charges, and reimbursements for persons with sickle cell disease. J Pediatr Hematol Oncol 1999; 21:389–96
   PubMed Web of Science ®Google Scholar
• Karnon J, Zeuner D, Brown J, . Lifetime treatment costs of beta-thalassaemia major. Clin Lab Haematol 1999; 21:377–85
   PubMedGoogle Scholar
• Wayne AS, Schoenike SE, Pegelow CH. Financial analysis of chronic transfusion for stroke prevention in sickle cell disease. Blood 2000; 96:2369–72
   PubMed Web of Science ®Google Scholar
• Mayer ML, Konrad TR, Dvorak CC. Hospital resource utilization among patients with sickle cell disease. J Health Care Poor Underserved 2003; 14:122–35
   PubMed Web of Science ®Google Scholar
• Desrosiers MP, Payne K, Proskorovsky I, . Estimated total annual costs of infused iron chelation therapy in the United Kingdom. Poster presented at the 11th Congress of the European Hematology Association (EHA). Abstract 0810 published in Haematologica/The Hematology Journal 2006;91(s1), (EHA)Amsterdam, The Netherlands17th June, 2006
   Google Scholar
• Brun-Strang C, Bachir D, De Montalembert M, . Socio-economic impact of infused iron chelation therapy in France: ISOSFER study results. Poster presented at the American Society of Hematology (ASH) Congress in 2006, Abstract 3354 published in Blood| 2006;108, 48th Annual CongressOrlando, Florida, US9-11 December, 2006
   Google Scholar
• Drummond MF, O'Brien B, Stoddart GL, . Methods for the economic evaluation of health care programmesOxford, (UK): Oxford University Press, 1997
   Google Scholar
• Van Roijen L, Essink-Bot ML, Koopmanschap MA, . Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire. Int J Technol Assess Health Care 1996; 12:405–15
   PubMed Web of Science ®Google Scholar
• Ware J Jr, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user's manualBoston (MA): The Health Institute, 1994
   Google Scholar
• Ware J Jr, Gandek B, Kosinski M, . The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA project [International Quality of Life Assessment]. J Clin Epidemiol 1998; 51:1167–70
   PubMed Web of Science ®Google Scholar
• Brooks R. Euroqol: the current state of play. Health Policy 1996; 37:53–72
   PubMed Web of Science ®Google Scholar
• Apolone G, Mosconi P, Ware JE Jr. Questionario sullo Stato di Salute SF-36. Manuale d'uso e guida all'interpretazione dei risultatiMilano, (Italy): Guerini e Associati, 1997
   Google Scholar
• Gringeri A, Mantovani LG, Scalone L, . Cost of care and quality of life for patients with haemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102:2358–63
   PubMed Web of Science ®Google Scholar
• Mantovani LG, Scalone L, Mannucci PM, . The cost of care of hemophilic patients without inhibitors: the COCHE study, Poster presented at the World Federation of Hemophilia (WFH) Congress in 2006. Abstract 28 PO 880. published in Haemophilia 2006; 12:(S2) 133–5
   PubMed Web of Science ®Google Scholar
• Abetz L, Baladi JF, Jones P, . The development of a treatment satisfaction questionnaire for iron overload (IO) patients on chelation therapy (CT). International Society for Pharmacoeconomics and Outcomes Research 8th Annual European CongressFlorence, ItalyNovember 6–8, 2005. Abstract n. PMC27 published in Value in Health 2005;8;A72
   Google Scholar
• Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16:297–334
   Web of Science ®Google Scholar
• Delea TE, Edelsberg J, Sofrygin O, . Consequences and costs of non-compliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 2007; 47:1919–29
   PubMed Web of Science ®Google Scholar
• Angelucci E, Barosi G, Camaschella C, . Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 2008; 93:1–12
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Bejaoui M, Agaoglu L, . Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther 2007; 29:909–17
   PubMed Web of Science ®Google Scholar